Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyActive Not Recruiting
NCT03703297Phase 3Updated Nov 21, 2025
Sponsor: AstraZeneca
Small Cell Lung Cancer
United States, Argentina, Belgium, Canada, China +14 more
Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC PatientsTerminated
NCT04412070N/AUpdated Nov 21, 2025
Sponsor: Hopital Foch
Bladder Cancer
France
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Completed
NCT04644237Phase 2Updated Nov 21, 2025
Sponsor: Daiichi Sankyo
Non-Small Cell Lung Cancer
United States, Australia, Canada, France, Italy +5 more
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLCCompleted
NCT02197234Phase 1Updated Nov 20, 2025
Sponsor: AstraZeneca
Non Small Cell Lung Cancer
United States, Belgium, France, South Korea, Spain
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)Completed
NCT02157883Phase 1Updated Nov 19, 2025
Sponsor: AstraZeneca
Advanced Non Small Cell Lung Cancer · Advanced (Inoperable) Non Small Cell Lung Cancer
United States, Belgium, Netherlands, South Korea, Taiwan +1 more
Effectiveness of Chat-based Mobile Application for Consultation (Zalo) in Improving Compliance With Follow-up Tests After Abnormal Chest X-ray Findings Interpret by Artificial IntelligentNot Yet Recruiting
NCT07234929NAUpdated Nov 19, 2025
Sponsor: Gia Dinh People Hospital
Lung Cancer · Tuberculosis (TB) · Chat-based Mobile Application · Compliance Behavior
Vietnam
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male SubjectsCompleted
NCT02612662Phase 1Updated Nov 19, 2025
Sponsor: AstraZeneca
Non-alcoholic Steatohepatitis (NASH)
United States
Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected AsthmaCompleted
NCT05992519N/AUpdated Nov 19, 2025
Sponsor: Université de Sherbrooke
Asthma · Asthma in Children · Diagnosis · Inflammation
Canada
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive Not Recruiting
NCT04042701Phase 1Updated Nov 18, 2025
Sponsor: Daiichi Sankyo
Breast Cancer · Non-small Cell Lung Carcinoma
United States, France, Spain, United Kingdom
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCCRecruiting
NCT07024680N/AUpdated Nov 18, 2025
Sponsor: AstraZeneca
Papillary Renal Cell Carcinoma
China
DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial InjuryCompleted
NCT02110303Phase 2, Phase 3Updated Nov 18, 2025
Sponsor: University of Edinburgh
Coronary Artery Disease
United Kingdom
Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)Completed
NCT04068168N/AUpdated Nov 17, 2025
Sponsor: AstraZeneca
Lung Cancer, Biliary Tract Cancer
South Korea
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With DyslipidemiaCompleted
NCT06173570Phase 2Updated Nov 17, 2025
Sponsor: AstraZeneca
Dyslipidemia
United States, Canada, Czechia, Denmark, Hungary +3 more
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.Completed
NCT06519968Phase 1Updated Nov 17, 2025
Sponsor: AstraZeneca
Healthy Participants
United Kingdom
Long-term Effect of Steroid on Metabolic Diseases in AsthmaticsCompleted
NCT06279078N/AUpdated Nov 17, 2025
Sponsor: Ajou University School of Medicine
Asthma · Osteoporosis, Osteopenia · Osteoporosis Risk · Osteoporotic Fractures
South Korea
A Disease Registry of Patients With Mantle Cell LymphomaCompleted
NCT03816683N/AUpdated Nov 14, 2025
Sponsor: AstraZeneca
Mantle Cell Lymphoma
United States
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABACompleted
NCT06020014Phase 2Updated Nov 13, 2025
Sponsor: AstraZeneca
Asthma
United States, Argentina, Brazil, Bulgaria, Denmark +13 more
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.Completed
NCT06742853Phase 1Updated Nov 10, 2025
Sponsor: AstraZeneca
Dyslipidemia
United States, United Kingdom
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy AdultsCompleted
NCT06469151Phase 1Updated Nov 10, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
Acalabrutinib for the Treatment of Chronic Graft Versus Host DiseaseActive Not Recruiting
NCT04198922Phase 2Updated Nov 5, 2025
Sponsor: Fred Hutchinson Cancer Center
Recurrent Moderate-Severe Chronic Graft Versus Host Disease · Hematopoietic and Lymphoid Cell Neoplasm
United States
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLCActive Not Recruiting
NCT03667820Phase 2Updated Nov 4, 2025
Sponsor: University of Texas Southwestern Medical Center
Non-small Cell Lung Cancer (NSCLC)
United States
Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234Completed
NCT06845813Phase 1Updated Nov 3, 2025
Sponsor: AstraZeneca
Renal Impairment
United States
A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor TreatmentCompleted
NCT06147830N/AUpdated Nov 3, 2025
Sponsor: AstraZeneca
Major Bleeding
United States, Germany, Japan, United Kingdom
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DMCompleted
NCT06327815Phase 4Updated Oct 31, 2025
Sponsor: AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
China
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.Completed
NCT05662033Phase 1Updated Oct 29, 2025
Sponsor: AstraZeneca
Inflammatory Diseases
United Kingdom

Previous page Next page